Patients with type O blood who carry alpha-gal antibodies from tick bites appear more likely to have severe allergic reactions when given plasma or platelets from type B or AB donors, according to a study of more than 550,000 transfusions published in JAMA Internal Medicine.
The research was led by pathologists at Dartmouth Health and the Geisel School of Medicine at Dartmouth, in collaboration with an international team, and was published in JAMA Internal Medicine on August 24; the institution described the finding as likely to change practice. Researchers propose the term transfusion-related alpha-gal syndrome (TRAGS). At the nine U.S. study sites in areas with high concentrations of alpha-gal syndrome, significantly more allergic transfusion reactions were reported among type O patients who received B or AB units than among those who received O units.
One hospital has already changed practice. Dartmouth-Hitchcock Medical Center has stopped giving B or AB platelets to type O patients, according to New Hampshire Public Radio.
The Biological Overlap That Makes the Association Plausible
The proposed mechanism rests on a structural resemblance between two sugars, and it is worth understanding because it explains why this risk was invisible for so long.
Alpha-gal is galactose-alpha-1,3-galactose, a sugar found in most non-primate mammals but absent in humans. A bite from the Lone Star tick can introduce it and prompt the immune system to produce alpha-gal-specific IgE antibodies. In people who become sensitized, eating beef, pork, lamb, dairy, or gelatin can trigger delayed reactions ranging from hives and abdominal pain to anaphylaxis.
The B blood group antigen is structurally similar to alpha-gal. Plasma and platelet units carry residual donor plasma, and the hypothesis is that alpha-gal IgE in a type O recipient cross-reacts with B antigen material in a B or AB unit. Type O recipients are the relevant group because they do not carry B antigen themselves.
That overlap has been suspected for several years. Published case reports describe type O patients with alpha-gal IgE who had severe reactions after receiving group B plasma or platelets, and one of those reactions was fatal. What this study adds is scale and a comparison group.
The Boundary Between Association and Proof in This Analysis
The design is observational, and the researchers are careful about the boundary.
The analysis covered more than 550,000 platelet and plasma transfusions at 40 sites across five countries, and found that severe reactions clustered in places where alpha-gal syndrome is more common. Separate French-led work published in the journal Blood reported that severe reactions in group O recipients of B or AB products were linked to alpha-gal sensitization, which supports the proposed mechanism.
What this cannot do is establish causation in any individual case, nor does it tell a patient their personal risk. Allergic reactions are among the more common transfusion complications, but life-threatening anaphylaxis is rare, and the previously documented triggers, including IgA and haptoglobin in deficient recipients, remain established mechanisms. TRAGS is an additional pathway rather than a replacement explanation, and the researchers note that further basic science and epidemiological work is needed.
The geographic condition is also a limit, not a footnote. The signal appeared in regions where alpha-gal sensitization is common. It should not be read as applying uniformly to every hospital in the country.
"We anticipate that this will change transfusion practices in the U.S.," said Dr. Richard M. Kaufman, the study's lead author and a professor of pathology and laboratory medicine at Geisel, adding that the change would likely be limited to high-prevalence regions.
Where the Exposure Actually Sits Geographically
The map matters here more than it does for most transfusion research, because sensitization follows tick range.
The CDC has estimated that as many as 450,000 people in the United States may have alpha-gal syndrome, and antibody surveillance suggests a much larger sensitized population. MedicalDaily reported on CDC seroprevalence testing across ten states, which found roughly one in four adults in five tick-heavy states carrying alpha-gal antibodies, with Arkansas highest at 31.2 percent, followed by Missouri, Virginia, Kentucky and Tennessee. That study also cautioned that a positive antibody test alone is not a diagnosis, since most sensitized people never develop symptoms.
Study senior author Dr. Nancy M. Dunbar attributed part of the trend to a warming climate and the resulting spread of ticks, which she said is producing illnesses and symptoms clinicians had not seen before. Sensitization has been documented in patients well outside the Lone Star tick's traditional southeastern range, and there is evidence that blacklegged tick bites can also cause the condition.
The Practical Takeaway for Patients Is Narrow and Specific
Almost nobody needs to act on this today, and the people who do are a defined group.
Patients with diagnosed alpha-gal syndrome who have type O blood and who are scheduled for surgery, chemotherapy, transplant, or any procedure likely to involve plasma or platelets can raise the finding with their surgeon, hematologist, or the hospital transfusion service in advance. That conversation is most useful before a planned procedure rather than during an emergency.
Patients with alpha-gal syndrome should already have it documented in their medical record alongside drug allergies, and this study is a reason to confirm that it is there. The condition also affects tolerance of certain medications and products derived from mammalian sources, so the record entry has value beyond transfusion.
Nobody should decline a medically necessary transfusion over this finding. In an emergency, the transfusion itself is the life-saving intervention, and the reactions described here are treatable when recognized. The researchers' recommendation is directed at hospital transfusion services choosing between compatible units, not at patients refusing care.
The study's authors also recommend that alpha-gal syndrome be investigated in any type O patient who has a severe allergic transfusion reaction after receiving B or AB components, with IgE testing and referral to an allergy specialist for those who test positive. That is the mechanism by which more cases will be identified.
Tick bite prevention remains the only intervention that addresses the underlying cause. Repellent, treated clothing and prompt tick removal reduce the sensitization that starts the chain. Whether blood banks outside high-prevalence regions will adopt similar restrictions is unresolved, and no national transfusion guideline has changed.
Key Questions Answered
What did the study find? Type O patients in high-prevalence regions had significantly more allergic reactions after receiving plasma or platelets from type B or AB donors, based on more than 550,000 transfusions at 40 sites across five countries.
Why would blood type matter for a meat allergy? The B blood group antigen is structurally similar to alpha-gal. Plasma and platelet units carry residual donor plasma, so alpha-gal IgE in a type O recipient may cross-react with B antigen material.
Does this prove the transfusions caused the reactions? No. This is observational research showing an association and a plausible mechanism. It cannot establish causation in an individual case, and the authors say more work is needed.
Has any hospital changed practice? Yes. Dartmouth-Hitchcock Medical Center has stopped giving B or AB platelets to type O patients. No national guideline has changed.
Who should raise this with their doctor? People with diagnosed alpha-gal syndrome who have type O blood, particularly before a planned procedure likely to involve plasma or platelets.
Should anyone refuse a transfusion because of this? No. A medically necessary transfusion is the life-saving intervention, and these reactions are treatable when recognized. The recommendation is directed at transfusion services selecting units.
Where is alpha-gal sensitization most common? Antibody surveillance found the highest rates in Arkansas, Missouri, Virginia, Kentucky, and Tennessee, though the Lone Star tick's range has been expanding northward.
